Prostate-specific antigen: Indications, interpretation and therapeutic consequences;Prostaatspecifiek antigeen (PSA): Indicatie, interpretatie en therapeutisch gevolg

Tijdschrift voor Geneeskunde

Volumn 64, Issue 12, 2008, Pages 609-613

  Verbaeys, C ^a,b   Oosterlinck, W ^a  

^a Universitair Ziekenhuis Gent

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER SCREENING; DIAGNOSTIC TEST; EARLY DIAGNOSIS; HUMAN; MORBIDITY; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW;

EID: 46749158790     PISSN: 0371683X     EISSN: None     Source Type: Journal    
DOI: 10.2143/TVG.64.12.2000338     Document Type: Review

References (13)

1. OOSTERLINCK W, DEKUYPER P, CHRISTIAENS T, DE MAESENEER J. Audit over niet-dringende verwijzingen door huisartsen naar een (academische) urologische polikliniek. Tijdschr Geneesk 2006; 62: 782-787.
2. POSTMA R, SCHRODER FH, VAN LEENDERS GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89-97.
3. AUS G, ABBOU CC, BOLLA M, et al. EAU guidelines on prostate cancer. European Association of Urology. Eur Urol 2005; 48: 546-551.
4. FANG J, METTER EJ, LANDIS P, CHAN DW, MORRELL CH, CARTER HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 411-416.
5. SCARDINO PT. The responsible use of antibiotics for an elevated PSA level. Nat Clin Pract Urol 2007; 4: 1.
6. VILLEIRS GM, VERSTRAETE KL, DE NEVE WJ, DE MEERLEER GO. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 2005; 76: 99-106.
7. THOMPSON IM, PAULER DK, GOODMAN PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
8. KUNDU SD, ROEHL KA, YU X, ANTENOR JA, SUAREZ BK, CATALONA WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007; 177: 505-509.
9. CARTER HB, PEARSON JD, METTER EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-2220.
10. KLOTZ L. Active surveillance for prostate for whom? J Clin Oncol 2005; 23: 8165-8169.
11. EPSTEIN JI, CHAN DW, SOKOLL LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-2411.
12. STAMEY TA, FREIHA FS, MCNEAL JE, REDWINE EA, WHITTEMORE AS, SCHMID HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (3 Suppl): 933-938.
13. STEYERBERG EW, ROOBOL MJ, KATTAN MW, VAN DER KWAST TH, DE KONING HJ, SCHRÖ DER FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 107-112.